摘要
探讨依托考昔对于膝骨关节炎的临床疗效。方法:选取我院2019年1月-2020年1月收治的123例膝骨关节炎患者,随机分为观察组63例和对照组60例。对照组给予口服塞来昔布治疗,观察组给予依托考昔治疗,比较2组临床疗效。结果:与对照组比,观察组治疗效果明显较高(P<0.05);治疗前2组患者膝关节功能评分比较并不存在显著差异性(P>0.05),治疗6周、12周之后与对照组比,观察组膝关节功能评分明显较低(P<0.05);治疗前2组患者关节肿胀积分和活动受限积分功能评分比较并不存在显著差异性(P>0.05),治疗后与对照组比,观察组关节肿胀积分和活动受限积分功能评分明显较低(P<0.05);治疗前2组患者的疼痛评分差异不明显(P>0.05),治疗后观察组患者的疼痛评分改善比对照组更明显(P<0.05);治疗前2组患者WOMAC指数比较并不存在显著差异性(P>0.05),治疗6周、12周之后与对照组比,观察组WOMAC指数明显较高(P<0.05);观察组出现恶心呕吐、皮疹、头痛等不良反应的患者明显少于对照组(P<0.05);观察组患者对功能维度、症状维度、总健康状况、单项问题等4个方面的评分均高于对照组(P<0.05),观察组患者生活质量的总评分高于对照组(P<0.05)。结论:膝骨关节炎患者接受依托考昔治疗可有效增强治疗疗效,促进患者膝关节功能改善,可推广使用。
Objective:To investigate the clinical effect of etocoxib on knee osteoarthritis.Methods:123 patients with knee osteoarthritis admitted to our hospital from January 2019 to January 2020 were selected and randomly divided into study group(63 cases)and control group(60 cases).The control group was given oral celecoxib treatment,and the study group was given etocoxib treatment.Results:Compared with the control group,the therapeutic effect of the study group was significantly higher(P<0.05).There was no significant difference in the knee function scores between the two groups before treatment(P>0.05).After 6 weeks and 12 weeks of treatment,the knee function scores of the research group were significantly lower than those of the control group(P<O.05).Before treatment,there was no significant dfference in the functional scores of joint swelling score and mobility limitation score between the two groups(P>0.05).After treatment,the functional scores of joint swelling score and mobility limitation score in the study group were significantly lower than those in the control group(P<0.05).There was no significant difference between the two groups before treatment(P>0.05),and the improvement of pain score in the study group was more obvious than that in the control group after treatment(P<0.05).Before treatment,there was no significant difference in THE WOMAC index between the two groups(P>0.05).After 6 and 12 weeks of treatment,the STUDY group had a significantly higher WOMAC index than the control group(P<O.05).The incidence of adverse reactions such as nausea and vomiting,rash and headache in the study group was significantly lower than that in the control group(P<0.05).The scores of functional dimension,symptom dimension,total health status and single problem in the study group were higher than those in the control group(P<0.05),and the total score of quality of life in the study group was higher than that in the control group(P<0.05).Conclusion:Etonoxib treatment for patients with knee osteoarthritis can effectively enhance the therapeutic effect,promote the improvement of knee function,and can be popularized.
作者
陈越
CHEN Yue(Department of orthopedics and traumatology,Chenghai hospital of traditional Chinese medicine,Shantou,Guangdong 515800)
出处
《中国伤残医学》
2022年第20期23-26,96,共5页
Chinese Journal of Trauma and Disability Medicine
